# China NMPA Drug Inspection - Hebei Renxin Pharmaceutical Co., Ltd. - Angelica sinensis (batch number 10719026)

Source: https://www.globalkeysolutions.net/records/china_drug_inspection/hebei-renxin-pharmaceutical-co-ltd/c8cfc598-0b45-467d-9470-f27485ffc0a9/
Source feed: China

> China NMPA drug inspection for Hebei Renxin Pharmaceutical Co., Ltd. published March 31, 2020. Drug: Angelica sinensis (batch number 10719026). The Hebei Provincial Drug Administration issued its first 2020 quality bulletin on March 31, following inspections condu

---

## Details

- Record Type: CHINA_DRUG_INSPECTION
- Title: Hebei Province Drug Quality Bulletin (2020 Drug Supervision and Sampling Inspection Issue 1)
- Company Name: Hebei Renxin Pharmaceutical Co., Ltd.
- Publication Date: 2020-03-31
- Drug Name: Angelica sinensis (batch number 10719026)
- Inspection Finding: The "Characteristics" item does not meet the requirements (infested with insects).
- Action Taken: The relevant drug regulatory authorities have taken control measures such as sealing and seizing in accordance with the law; they have filed cases to investigate illegal acts of producing and selling substandard drugs and taken necessary risk control measures.
- Summary: The Hebei Provincial Drug Administration issued its first 2020 quality bulletin on March 31, following inspections conducted under the provincial drug supervision and sampling plan. The report details quality failures across several pharmaceutical entities, including Jilin Tonghua Boxiang Pharmaceutical Co., Ltd., Anguo Shenghe Pharmaceutical Co., Ltd., Hebei Renxin Pharmaceutical Co., Ltd., Jiuquan Peifeng Traditional Chinese Medicine Ecological Planting and Processing Co., Ltd., and Anguo Yuanguang Pharmaceutical Co., Ltd. Main violations centered on structural and physical non-compliance. Specifically, cold soft capsules failed disintegration requirements, while various traditional Chinese medicine products, such as Angelica sinensis and Trichosanthes kirilowii, were found to be infested with insects. These failures represent significant deviations from required safety and efficacy standards. Regulated under the Drug Administration Law of the People's Republic of China, authorities have already implemented control measures, including the sealing and seizure of defective batches. The administration has ordered formal investigations and prosecutions of the manufacturers and distributors involved. Required actions include mandatory risk control measures and a public reporting of case resolutions within three months. Any findings of counterfeit products or potential criminal activity must be referred to public security departments for further prosecution.

Company: https://www.globalkeysolutions.net/companies/hebei-renxin-pharmaceutical-co-ltd/03d34769-b061-457b-a903-f9b9a303d587/